Supplemental Material

Journal: European Journal of Drug Metabolism and Pharmacokinetics

Pharmacokinetics and safety of dabigatran etexilate after single and multiple oral doses
in healthy Chinese subjects

Jingli Duan\textsuperscript{1,2*}, Li Yang\textsuperscript{1}, Haiyan Li\textsuperscript{3}, Norio Yamamura\textsuperscript{4}, Akiko Harada\textsuperscript{4}

\textsuperscript{1}Department of Pharmacy, Peking University Third Hospital, Peking, China
\textsuperscript{2}Department of Pharmacy, Peking University International Hospital, Peking, China
\textsuperscript{3}Department of Cardiovascular, Peking University Third Hospital, Peking, China
\textsuperscript{4}Department of Clinical Pharmacokinetics/Pharmacodynamics, Nippon Boehringer Ingelheim Co., Ltd.
Kobe, Japan

Corresponding author contact information:

Name: Jingli Duan
Phone: 861069006062
Fax: 861069006062
Email: duanjingli@pkuih.edu.cn

Physical address: No. 1 Life Park Road, Life Science Park of Zhongguangcun, Changping District,
Beijing, China.102206
Table I  Inclusion and exclusion criteria

**Inclusion criteria**

1. Healthy subjects based upon a complete medical history, including the physical examination, vital signs, 12-lead ECG, clinical laboratory tests
2. Age: ≥18 and ≤45 years
3. Body Mass Index (BMI): ≥18 and <25 kg/m²

**Exclusion criteria**

1. Current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders.
2. Subject cannot use an adequate form of contraception from the time of the first dose on Day 1 up to end-of study examination.
3. Current diseases of the central nervous system (such as epilepsy), or psychiatric disorders or neurological disorders.
4. History of clinically significant orthostatic hypotension, clinically significant current or past fainting spells or blackouts.
5. Chronic or relevant acute infections.
6. History of
   - allergy/hypersensitivity (including drug allergy) which was deemed relevant to the safety assessment as judged by the investigator (excluding asymptomatic seasonal rhinitis/hay fever).
   - any bleeding disorder including prolonged or habitual bleeding.
   - other hematologic diseases.
   - cerebral bleeding (e.g. after a car accident).
   - concussions (head trauma resulting in injuring to brain) with or without loss of consciousness.
7. Intake of drugs with a long half-life (> 24 hours) within at least 1 month or less than 10 half-lives, whichever was shorter, of the respective drug prior to administration or during the trial.
8. Use of aspirin (including over-the-counter medications), antiplatelet agents like ticlopidine or dipyridamole, chronic administration of NSAIDs, coumadin like anticoagulants, chronic use of corticosteroids, heparin or fibrinolytic agents within 14 days prior to administration up to end-of-study examination.

9. Participation in another trial with an investigational drug within 3 months prior to administration up to end-of-study examination.

10. Smoker (>10 cigarettes/day or inability to refrain from smoking during the trial).

11. Alcohol abuse (more than 60 g/day; confirmed by interview).

12. Drug abuse (confirmed by interview).

13. Blood donation (more than 100 mL from 3 months prior to screening and any blood donation from screening up to end-of-study examination).

14. Excessive physical activities (within 7 days prior to the first drug administration up to end-of-study examination).

15. Any laboratory value outside the reference range that is of clinical relevance.

16. Known hypersensitivity to the investigational drug or its excipients.

17. Subject who was judged ineligible by the investigator or the sub-investigator.

18. History of any familial bleeding disorder.

19. Thrombocytes <100×10^9.

20. Pregnant female subjects.
Table II  Flow Chart for subjects screening and recruitment

| Day     | -14 ~ -2 | -1 | 1                  |
|---------|----------|----|--------------------|
| Clock Time | 17:00    | 20:00 | 6:00    | 8:00 |
|          | Screening examination | Admission to study center | Dinner | Drug administration immediately after breakfast |
| Informed consent | X | X |        |      |
| Randomization |        | X |        |      |
| Physical examination | X | X | X |      |
| Syphilis & virus screening | X |        |      |      |
| Inclusion/exclusion criteria | X |        | X |      |
| Drug administration |        |        |      | X |
| PK blood sampling |        |        |      | X |
| Fecal occult blood test |        |        |      |      |
| Laboratory test, urine test | X |        | X |      |
| Vital sign | X |        | X |      |
| Adverse event |        |        |      |      |
| 12-lead ECG | X |        | X |      |